Abstracts tagged "remission and rheumatoid arthritis (RA)"

Abstract Number: 2127 • 2014 ACR/ARHP Annual Meeting
Subclinical Arthritis Is Detected By Macrophage Targeting and Positron Emission Tomography (PET) in Early RA Patients in Clinical Remission
Y.Y.J. Gent¹, M.M. ter Wee¹, D den Uyl¹, N. Ahmadi², W.F. Lems³, O.S. Hoekstra⁴, A.E. Voskuyl¹ and C.J. Van der Laken³, ¹Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ²Radiology, VU University Medical Center, Amsterdam, Netherlands, ³Rheumatology, VU Medical Center, Amsterdam, Netherlands, ⁴Nuclear Medicine, VU Medical Center, Amsterdam, Netherlands
Background/Purpose: Recurrent flares in RA patients in complete remission (CR) are not an uncommon phenomenon. Studies with advanced imaging techniques have suggested that residual subclinical…
Abstract Number: 2028 • 2014 ACR/ARHP Annual Meeting
Effect of Age at Rheumatoid Arthritis Onset on Clinical, Radiographic, and Functional Outcomes: The Espoir Cohort
Thomas Krams¹, Adeline Ruyssen-Witrand², Delphine Nigon¹, Bruno Fautrel^3,4,5, Francis Berenbaum^6,7, Alain G. Cantagrel⁸ and Arnaud Constantin⁹, ¹Rhumatologie, Purpan University Hospital, Toulouse, France, ²Rheumatology, Purpan University Hospital, Toulouse, France, ³Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ⁴Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France, ⁵Rheumatology, Pitie Salpetriere Hospital, Paris, France, ⁶Service de Rhumatologie, Saint-Antoine Hospital, Paris, France, ⁷INSERM - UMR S 938, Paris, France, ⁸Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ⁹Rheumatology, Purpan University Hospital, Toulouse Cedex 9, France
Background/Purpose: Rheumatoid arthritis (RA) is a chronic disease with peak incidence in the fourth and fifth decades of age. To investigate whether age at disease…
Abstract Number: 1479 • 2014 ACR/ARHP Annual Meeting
Impact of Clinical Remission on Physical Function in Patients with Rheumatoid Arthritis Treated with ALX-0061: Post-Hoc Analysis of Phase I/II Data
Katrien Van Beneden¹, Katrien Verschueren¹, Wouter Willems¹, Heidi Wouters¹, Joke D'Artois¹, Katelijne De Swert¹, Steven De Bruyn¹ and Gerhard Arold², ¹Clinical Development, Ablynx nv, Zwijnaarde, Belgium, ²Medical Affairs, PRA International GmbH, Berlin, Germany
Background/Purpose: ALX-0061 is a monovalent IL-6R targeting Nanobody, inhibiting signaling via soluble and membrane IL-6R. The safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of ALX-0061 was…
Abstract Number: 1420 • 2014 ACR/ARHP Annual Meeting
Non-Use of Glucocorticoid and Osteoarthritis Absence As Predictors of Clinical Remission in AR
Salvador Loredo-Alanís¹, David Vega-Morales², Mario Garza-Elizondo¹, Mario Garcia-Pompermayer³, Roberto Negrete-López¹, Daniel Treviño-Montes¹ and Diana Flores-Alvarado², ¹Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Rheumatology, Hospital Universitario UANL, Monterrey, Mexico, ³Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterey, Mexico
Background/Purpose The clinical evaluation of Rheumatoid arthritis (RA) is accomplished with compound indexes allowing better clinical decision. Clinical remission nowadays is an attainable target in…
Abstract Number: 944 • 2014 ACR/ARHP Annual Meeting
Predict the Chance of Remission for Your RA Patient in Real Life
Till Uhlig¹, Vibeke Norvang², Elisabeth Lie¹, Erik Rødevand³, Knut Mikkelsen⁴, Åse S. Lexberg⁵, Synøve Kalstad⁶ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, ⁴Revmatismesykehuset, Lillehammer, Norway, ⁵Dept. of Rheumatology, Vestre Viken Hospital, Drammen, Norway, ⁶Rheumatology, University Hospital of Northern Norway, Tromsø, Norway
Background/Purpose: Clinical remission (REM) is the treatment target in rheumatoid arthritis (RA), and there are several composite REM criteria available. Knowledge on how disease duration affects REM…
Abstract Number: 1311 • 2013 ACR/ARHP Annual Meeting
Aiming Simple Disease Activity Score Remission At One Year Leads To Better 3-Year Radiographic and Functional Outcomes Than aiming low Disease activity in Early Rheumatoid Arthritis Patients Treated In Routine Practice. Data From Espoir Cohort
Adeline Ruyssen-Witrand¹, Gregory Guernec², Delphine Nigon³, Gabriel Tobon⁴, Bénédicte Jamard⁵, Anne-Christine Rat⁶, Olivier Vittecoq⁷, Alain G. Cantagrel⁸ and Arnaud L. Constantin¹, ¹Rheumatology, Purpan University Hospital, Toulouse, France, ²UMR 1027, Inserm, Toulouse, France, ³Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ⁴Unit of immunology, Brest, France, ⁵Toulouse University Hospital, Toulouse, France, ⁶Université de Lorraine, Nancy, F-54000, France; Inserm, CIC-EC CIE6, Nancy, F-54000, France; CHU de Nancy, Clinical Epidemiology and Evaluation Department, Nancy, F-54000, France; CHU de Nancy, Rheumatology department, Nancy, France, ⁷Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France, ⁸Centre Hospitalier Universitaire de Toulouse, Toulouse, France
Background/Purpose: The ultimate goal of Disease Modifying Anti-Rheumatic Drugs (DMARDs) treatment in early rheumatoid arthritis (RA) is to achieve remission in order to prevent structural…
Abstract Number: 490 • 2013 ACR/ARHP Annual Meeting
Does Low Disease Activity At Six Months Predict Remission At 12 Months In Rheumatoid Arthritis Patients Treated With Biologics In a Real–World Setting?
Philip Baer¹, William G. Bensen², Andrew Chow³, Rafat Y. Faraawi^4,5, Denis Choquette⁶, Isabelle Fortin⁷, John T. Kelsall⁸, Dalton E. Sholter⁹, Emmanouil Rampakakis^10,11, John S. Sampalis^10,11, Francois Nantel¹², Allen J. Lehman¹³, May Shawi¹⁴ and Susan M. Otawa¹³, ¹Private Practice, Scarborough, ON, Canada, ²Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ³University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁴Rheumatologist, KW Musculoskeletal Research Inc., Kitchener, ON, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁷Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁸Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁹Rheumatology Associates, Edmonton, AB, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Jewish General Hospital, McGill University, Montreal, QC, Canada, ¹²Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁴Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: Remission is considered the treatment goal in the management of patients with rheumatoid arthritis (RA). The objective of this analysis was to determine if…
Abstract Number: 2691 • 2013 ACR/ARHP Annual Meeting
Results Of The Strass Trial Regarding Impact Of Progressive Spacing Of Tnf-Blocker Injections In Rheumatoid Arthritis Patients In Das28 Remission: Is There a Difference Between Drugs – Adalimumab and Etanercept – Or Their Mode Of Use – Monotherapy Or Combination?
Bruno Fautrel¹, Thao Pham², Jacques Morel³, Toni Alfaiate⁴, Emmanuelle Dernis⁵, Philippe Gaudin⁶, Olivier Brocq⁷, Elisabeth Solau-Gervais⁸, Jean-Marie Berthelot⁹, Jean-Charles Balblanc¹⁰, Xavier Mariette¹¹ and Florence Tubach¹², ¹Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France, ²Rheumatology Department, Sainte Marguerite Hospital, Marseille, France, ³Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ⁴Biostatistics, Bichat Hospital, AP-HP, Paris, France, ⁵Le Mans Hospital, Le Mans, France, ⁶Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁷Hospital of Princesse Grâce de Monaco, Monaco, France, ⁸Rheumatology, University Hospital of Poitiers, Poitiers, France, ⁹Rheumatology Unit, Nantes University Hospital, Nantes, France, ¹⁰Rheumatology, Centre Hospitalier Général de Belfort, Belfort, France, ¹¹Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ¹²INSERM, Universite Paris Diderot, Paris, France
Background/Purpose: The STRASS trial was an 18-month randomized controlled trial, conducted in established RA patients in DAS28 remission with etanercept (ETA) or adalimumab (ADA), comparing…
Abstract Number: 2388 • 2013 ACR/ARHP Annual Meeting
Predictive Factors Of Relapse Or Persistent Stable Remission For Rheumatoid Arthritis (RA) Patients In Remission in a TNF Blocker-Spacing Strategy Trial (STRASS Trial)
Thao Pham¹, Jacques Morel², Toni Alfaiate³, Emmanuelle Dernis⁴, Philippe Gaudin⁵, Olivier Brocq⁶, Elisabeth Solau-Gervais⁷, Jean-Marie Berthelot⁸, Jean-Charles Balblanc⁹, Xavier Mariette¹⁰, Florence Tubach¹¹ and Bruno Fautrel¹², ¹Rheumatology Department, Sainte Marguerite Hospital, Marseille, France, ²Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ³Biostatistics, Bichat Hospital, AP-HP, Paris, France, ⁴Le Mans Hospital, Le Mans, France, ⁵Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁶Hospital of Princesse Grâce de Monaco, Monaco, France, ⁷Rheumatology, University Hospital of Poitiers, Poitiers, France, ⁸Rheumatology Unit, Nantes University Hospital, Nantes, France, ⁹Rheumatology, Centre Hospitalier Général de Belfort, Belfort, France, ¹⁰Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ¹¹INSERM, Universite Paris Diderot, Paris, France, ¹²Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France
Background/Purpose: The STRASS trial was a 18-month randomized controlled trial, conducted in established RA patients in DAS28 remission with etanercept (ETA) or adalimumab (ADA), comparing…
Abstract Number: 2341 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Adalimumab Plus Methotrexate Therapy In Rheumatoid Arthritis Non-Responders Receiving Methotrexate Monotherapy Or Adalimumab Combination Therapy: Results From The Optima Trial
Josef S. Smolen¹, Ronald F. van Vollenhoven², Roy Fleischmann³, Paul Emery⁴, Stefan Florentinus⁵, Suchitrita S. Rathmann⁶, Anabela Cardoso⁷, Hartmut Kupper⁸ and Arthur Kavanaugh⁹, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²The Karolinska Institute, Stockholm, Sweden, ³University of Texas Southwestern Medical Center, Dallas, TX, ⁴Leeds Teaching Hospital, Leeds, United Kingdom, ⁵AbbVie, Rungis, France, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie, Amadora, Portugal, ⁸AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ⁹University of California, San Diego, La Jolla, CA
Background/Purpose: EULAR recommendations advocate Methotrexate (MTX) as first line therapy. For patients (pts) who fail to attain remission or low disease activity (LDA) after 6…
Abstract Number: 2250 • 2013 ACR/ARHP Annual Meeting
What Is The Real World Relationship Between Patient-Reported Pain Or Patient Global Assessment and Disease Activity Indices In Rheumatoid Arthritis? An Analysis From The Prospective, Observational, Biologic Treatment Registry Across Canada
Regan Arendse¹, Michael Starr², Proton Rahman³, John T. Kelsall⁴, Milton F. Baker⁵, William Bensen⁶, J. Carter Thorne⁷, Philip Baer⁸, Denis Choquette⁹, Isabelle Fortin¹⁰, Emmanouil Rampakakis¹¹, John S. Sampalis¹¹, Susan M. Otawa¹², May Shawi¹³, Francois Nantel¹⁴ and Allen J. Lehman¹², ¹University of Saskatchewan, Saskatoon, SK, Canada, ²Montreal General Hospital, Montreal, QC, Canada, ³Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁵University of Victoria, Victoria, BC, Canada, ⁶St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸Private Practice, Scarborough, ON, Canada, ⁹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ¹⁰Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada, ¹⁴Janssen Inc., Toronto, ON, Canada
Background/Purpose: Patient-reported outcomes such as pain and patient global assessment of disease activity (PtGA) have been critiqued for not accurately assessing rheumatoid arthritis (RA) disease…
Abstract Number: 2246 • 2013 ACR/ARHP Annual Meeting
Patients’ Assessment of the Disease Greatly Influences the Determination of Disease Activity and Remission in Rheumatoid Arthritis
Kenrin Shi^1,2, Kenji Miki^1,3, Masao Yukioka¹, Kosuke Ebina², Shoichi Kaneshiro² and Hideki Yoshikawa², ¹Department of Orthopaedic Surgery, Yukioka Hospital, Osaka, Japan, ²Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan, ³Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan
Background/Purpose: Recently defined remission criteria of rheumatoid arthritis (RA), Boolean criteria or Simplified Disease Activity Index (SDAI)
Abstract Number: 1433 • 2013 ACR/ARHP Annual Meeting
Lack Of Early Clinical Response To Treatment With Baricitinib Predicts Low Probability Of Achieving Long Term DAS28-ESR Low Disease Activity Or Remission In Patients With Rheumatoid Arthritis
Edward Keystone¹, MC Genovese², Peter Taylor³, Baojin Zhu⁴, Scott D. Beattie⁴, Stephanie de Bono⁴, Terence Rooney⁴, Douglas E. Schlichting⁴ and William Macias⁴, ¹University of Toronto, Toronto, ON, Canada, ²Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, ³NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ⁴Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib, an oral inhibitor of JAK1 and JAK2 activity, was investigated as treatment for patients with moderately to severely active RA despite use…
Abstract Number: 1342 • 2013 ACR/ARHP Annual Meeting
Prognosis In Espoir Rheumatoid Arthritis Cohort At 24 Months According To Remission Status At 12 Months: No Differences In Radiographic Scores According To Prior Remission Status, But Significant Differences In HAQ Scores, Highest For Boolean and RAPID3RJ1 Criteria
Isabel Castrejón¹, Maxime Dougados², Bernard Combe³, Francis Guillemin⁴, Bruno Fautrel⁵ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Cochin Hospital, Paris, France, ³CHU Lapeyronie, Montpellier, France, ⁴Hopitaux de Brabois, Nancy, France, ⁵APHP, Pitié-Salpêtrière University Hospital, Paris, France
Background/Purpose: Different criteria for remission in rheumatoid arthritis (RA) have been developed from a Core Data Set of 7 measures for the DAS28, SDAI, CDAI…
Abstract Number: 1352 • 2013 ACR/ARHP Annual Meeting
What Factors Lead To Achieve and Sustain Remission In Rheumatoid Arthritis Patients With Moderate To High Disease Activity?
Soo-Kyung Cho^1,2, Yoon-Kyoung Sung^1,2, Jeeseon Shim³, Chan-Bum Choi^4,5, Jung-Yoon Choe⁶, Won Tae Chung⁷, Seung-Jae Hong⁸, Jae-Bum Jun⁵, Tae-Hwan Kim⁹, Tae-Jong Kim¹⁰, Eun-Mi Koh¹¹, Jisoo Lee¹², Shin-Seok Lee¹⁰, Sung Won Lee¹³, Dae-Hyun Yoo⁵ and Sang-Cheol Bae^1,2, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Department of Rheumatology, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ³Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁵Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁶Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁷Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital, Busan, South Korea, ⁸Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, ⁹Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹⁰Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ¹¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ¹²Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, South Korea, ¹³Rheumatology, Dong-A University Hospital, Busan, South Korea
Background/Purpose: Clinical remission has now become the treatment goal in rheumatoid arthritis (RA), but it is not common in clinical practice. This study aimed to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].